Total trials
3,521
Capped at 5,000
Active
341
Phase 3
1,112
Total enrollment
5,232,581
Pipeline matrix
Showing 40 of 274 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ribociclib | — | 33 | |||||
| Fulvestrant | — | — | 24 | ||||
| Inclisiran | — | — | 18 | ||||
| Letrozole | — | 47 | |||||
| Trametinib | — | 28 | |||||
| AAA617 | — | — | 7 | ||||
| Secukinumab | — | 72 | |||||
| Ruxolitinib | — | 25 | |||||
| Dabrafenib | — | 25 | |||||
| Ofatumumab | — | 24 | |||||
| Standard of Care | — | — | — | 13 | |||
| Nilotinib | — | 53 | |||||
| Fingolimod | — | 31 | |||||
| Crizanlizumab | — | — | 9 | ||||
| Anastrozole | — | — | 6 | ||||
| Imatinib | — | — | 22 | ||||
| Goserelin | — | — | 11 | ||||
| SoC | — | — | — | — | 3 | ||
| Bosutinib | — | — | — | — | 3 | ||
| Dasatinib | — | — | — | 3 | |||
| Asciminib single agent | — | — | — | — | 2 | ||
| Everolimus | — | 105 | |||||
| Ceritinib | — | 12 | |||||
| Inclisiran sodium | — | — | 7 | ||||
| Atorvastatin | — | — | — | — | 2 | ||
| Tamoxifen | — | — | — | 4 | |||
| Usual care | — | — | — | — | — | 2 | |
| Disease modifying treatment | — | — | — | — | — | 1 | |
| Ofatunumab | — | — | — | — | — | 1 | |
| Secukinumab s.c. | — | — | — | — | — | 1 | |
| Onasemnogene Abeparvovec-brve | — | — | — | — | — | 1 | |
| KJX839 | — | — | — | — | — | 1 | |
| Asciminib single agent pediatric formulation | — | — | — | — | — | 1 | |
| Panobinostat | — | 22 | |||||
| Ianalumab | — | — | 16 | ||||
| Iptacopan | — | — | 18 | ||||
| Remibrutinib | — | — | 14 | ||||
| Alpelisib | — | 23 | |||||
| Pelabresib | — | — | — | — | 6 | ||
| Pelacarsen | — | — | — | 7 |
234 more active programs hidden
Next readouts
- 2016-12-07
- 2017-07-14
- 2022-06-09
- 2022-08-31
- 2022-10-02
- 2023-05-26
- 2023-08-23
- 2023-11-28
- 2024-03-20
- 2024-07-02
Top conditions
- Hypertension160
- Asthma82
- Breast Cancer73
- Diabetes Mellitus, Type 265
- Chronic Obstructive Pulmonary Disease57
- Multiple Sclerosis47
- Healthy45
- Influenza44
Frequently asked questions about Novartis
- How many clinical trials does Novartis have on ClinicalTrials.gov?
- Novartis is listed as the lead sponsor on 3,521 clinical trials in ClinicalTrials.gov, 341 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Novartis's trials are in Phase 3?
- 1,112 of Novartis's trials are in Phase 3, spread across 274 active drug programs.
- What therapeutic areas does Novartis focus on?
- Novartis's most-studied conditions on ClinicalTrials.gov are Hypertension, Asthma, Breast Cancer, Diabetes Mellitus, Type 2, Chronic Obstructive Pulmonary Disease.
- When are Novartis's next clinical trial readouts?
- Novartis has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations”, expected around 2016-12-07.